Massachusetts-based Revvity, Inc. (RVTY) is a global life sciences and diagnostics company that provides instruments, reagents, software, and services to support drug discovery, clinical research, and medical diagnostics. Valued at $9.5 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. Companies worth $10 billion or more are generally described as “large-cap st ...

Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q4 2025 investor letter for the “Growth Equity Strategy.” A copy of the letter is available to download here. In 2025, the strategy returned +3.1% (gross) and +3.0% (net), resulting in the year-to-date return of 16.7% (gross) and +16.0% (net). Discussions on a potential bubble in Artificial Intelligence (AI) markets were a significant feature of 2025, especially in Q4, contributing to a pullback in AI sto ...

Group 1 - The company has recently gained recognition for its Signals business, particularly following updates related to AI technology [1] - Significant launches across the platform are expected to enhance the company's market position and customer engagement [1] - The discussion highlights the importance of customer stickiness and data access in the context of the company's offerings [2] Group 2 - AI is perceived as a critical factor in the company's ability to capture market share, addressing both opportunities and concerns within the industry [2]

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - **Company**: Revvity - **Industry**: Life Science Tools and Diagnostics Key Points and Arguments Signals Business and AI Integration - The Signals platform is described as a deeply embedded scientific platform essential for research, with AI acting as an accelerator rather than a disruptor [2][2] - There is a significant disconnect between external perceptions of AI's impact and internal expectations regarding its enhancement of the Signals business [2][2] - The current portfolio includes ChemDraw, Signals One, and Spotfire, which are foundational tools for research scientists [6][10] - New product launches include BioDesign, LabGistics, and Xynthetica, which are expected to enhance the Signals platform [3][22] New Product Launches - **BioDesign**: A large molecule version of ChemDraw, filling a gap in the portfolio for designing biomolecules [22][22] - **LabGistics**: A platform for capturing complex workflows in laboratories, enhanced by AI [25][25] - **Xynthetica**: Provides operational access to machine learning models for research, likened to an iOS for the Signals platform [28][34] Financial Guidance and Market Position - The company anticipates a growth rate of 9%-11% for the Signals business, with expectations of exceeding previous annual portfolio value metrics [52][55] - The guidance for the year is conservative at 2%-3%, factoring in potential headwinds from China and a soft market for NIH and academic funding [62][72] - The company has successfully absorbed significant tariff impacts while maintaining growth, indicating resilience in a challenging market [66][66] Competitive Landscape - Revvity has gained market share in a depressed environment, focusing on service, quality, and timely delivery as key differentiators [92][95] - The company emphasizes the importance of scientific innovation and collaboration with customers to maintain its competitive edge [97][99] Diagnostics Business in China - The Immunodiagnostics segment in China is expected to contribute less than 5% to total business, with known impacts from policy changes already accounted for [116][121] - The company remains cautious about potential unknown policy headwinds that could affect this segment [121][121] Long-term Outlook - The company is optimistic about the potential for growth in the Signals business, with a goal to double its size within the next 4-5 years [60][60] - The focus remains on innovation and adapting to market needs, particularly in the context of evolving clinical diagnostics [125][125] Additional Important Insights - The integration of AI into existing platforms is seen as a critical factor for future growth and competitiveness [11][15] - The company is actively engaging with customers to ensure that new product developments align with market needs and expectations [46][46] - The overall sentiment is one of cautious optimism, with a clear strategy to navigate potential market disruptions while capitalizing on new opportunities [72][72]

Group 1: Fund Performance - Bretton Fund returned 1.44% in Q4 2025 compared to 2.66% for the S&P 500 Index [1] - For the full year 2025, the Fund returned 11.58% versus 17.88% for the Index [1] - The firm views the overall market as modestly elevated but not in bubble territory [1] Group 2: Investment Strategy - The Fund is focusing on areas of value that will provide good returns over the long term [1] - The Fund is willing to reduce speculative elements of the AI boom, even if it leads to temporary lag during strong market phases [1] Group 3: Revvity, Inc. (NYSE:RVTY) Overview - Revvity, Inc. has a market capitalization of $11.166 billion [2] - The stock closed at $98.49 per share on March 04, 2026, with a one-month return of -1.03% and a 52-week loss of 13.00% [2] Group 4: Revvity, Inc. Investment Analysis - The Fund invested in Revvity, Inc. due to its potential in the health sciences sector but faced challenges due to management decisions [3] - The overall return on the investment in Revvity, Inc. was -28.5%, with a -5.90% IRR [3] - Revvity, Inc. is not among the 40 Most Popular Stocks Among Hedge Funds, with 35 hedge fund portfolios holding it at the end of Q4, up from 22 in the previous quarter [4] Group 5: Comparative Investment Potential - The firm believes certain AI stocks offer greater upside potential and carry less downside risk compared to Revvity, Inc. [4] - A report on undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend is available [4]

Core Insights - Revvity reported Q4 2025 adjusted earnings per share of $1.70, exceeding the Zacks Consensus Estimate of $1.63 by 4.3%, and showing a 19.7% improvement year-over-year [2] - The company’s revenues reached $772.1 million, reflecting a 5.9% year-over-year increase and nearly aligning with estimates [3] Revenue Details - Revenues from the Life Sciences segment totaled $382 million, remaining flat organically year-over-year, while adjusted operating income decreased by 1.4% to $136 million [4] - The Diagnostics segment generated revenues of $390 million, marking a 10% year-over-year increase, with a 7% organic growth [4] Margin Analysis - Selling, general and administrative expenses rose by 3% to $251.7 million, while research and development expenses increased by 18.2% to $58.2 million [6] - Adjusted operating income declined by 3.6% to $229.4 million, resulting in an adjusted operating margin of 29.7%, down 60 basis points from the previous year [6] Financial Update - At the end of Q4 2025, the company had cash and cash equivalents of $919.9 million, a slight decrease from $931.4 million in the prior quarter [7] - Cumulative net cash from operating activities was $582.9 million, down from $628.3 million in the year-ago quarter [7] 2026 Guidance - For 2026, Revvity anticipates adjusted earnings per share between $5.35 and $5.45, with revenues expected to be in the range of $2.96 to $2.99 billion [9] Estimate Revisions - There has been a downward trend in estimates, with the consensus estimate shifting down by 7.66% over the past month [10] VGM Scores - Revvity holds a Growth Score of B, a Momentum Score of C, and a Value Score of C, resulting in an aggregate VGM Score of B [11] Industry Performance - Revvity operates within the Zacks Medical Services industry, where HCA Healthcare has seen an 8.5% increase in stock price over the past month, reporting revenues of $19.51 billion, a 6.7% year-over-year change [13]

Group 1 - The company reported a strong performance in Q4, with positive results from both end markets and product execution [2] - In the diagnostics segment, reproductive health and newborn screening performed particularly well, while immunodiagnostics showed strong results outside of China [2] - The company observed stabilization in the pharma biotech sector, which positively influenced its overall results [2] Group 2 - The company executed effectively across its profit and loss statement, positioning itself favorably for 2026 [3]

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - **Company**: Revvity - **Industry**: Healthcare Diagnostics and Life Sciences Key Points Financial Performance and Guidance - Q4 performance was strong, particularly in reproductive health and newborn screening, with better-than-expected results in China despite market pressures [4][92] - The company maintains a 2%-3% organic growth guidance for 2026, with expectations for margin expansion driven by cost measures implemented in Q4 2025 [5][7] - Positive margin expansion is anticipated to continue into 2027, particularly in the first half [6] Market Conditions - The pharma biotech market is stabilizing, with signs of funding and M&A activity increasing, indicating a shift from cost-cutting to growth and investment [19][21] - The Life Science Solutions segment is expected to see growth, with a focus on reagent sales, which have shown positive growth in four out of five quarters [11][36] - The preclinical market remains weak, but improvements in instrument sales are expected to drive reagent sales higher [10][12] Product Segments - **Immunodiagnostics**: The U.S. market has grown from 5% to 20% of total revenue since the acquisition of Euroimmun, with expectations for further growth driven by autoimmune disease testing [75][77] - **Reproductive Health**: The newborn screening business is expected to continue its outsized growth, supported by new disorder approvals and geographic expansion [104][109] - **Software (Revvity Signals)**: Positioned as a beneficiary of AI developments, with the launch of Synthetica expected to enhance the platform's capabilities [48][49] Competitive Positioning - Revvity has gained market share in the reagent business despite a depressed market, attributed to a strong portfolio and customer stickiness [36][40] - The company is focused on maintaining a competitive edge through continuous product launches and addressing customer needs [55][56] Strategic Initiatives - The company has repurchased 15 million shares over the past two and a half years, indicating confidence in its stock value [120] - Future M&A activities will focus on bolt-on acquisitions that align strategically with Revvity's portfolio [121][124] Challenges and Risks - The guidance for China diagnostics has been conservative, with expectations for a decline in the mid-20s, reflecting ongoing uncertainties in the market [92][93] - The company acknowledges the need to demonstrate consistent performance to gain market confidence, particularly in a recovering environment [125][138] Management Compensation - Management compensation is tied to organic growth, operating margin expansion, and cash flow conversion, with a focus on three-year targets [97][100] Future Outlook - The company aims for significant growth in the Signals business, with expectations to double revenue in the next five years, driven by new product launches and market opportunities [61][70] Conclusion - Revvity is positioned for growth in 2026 and beyond, with a focus on executing its strategic initiatives, expanding its product offerings, and navigating market challenges effectively [138]

Company Overview - Revvity has undergone significant transformation over the past decade, evolving its business composition and expanding its capabilities [2][3] - Approximately 10 years ago, Revvity's business was divided into three equal parts: Analytical, Life Sciences, and Diagnostics [3] Life Sciences and Diagnostics Expansion - The Life Sciences segment initially focused on small molecules in preclinical research, while the Diagnostics segment was limited to reproductive health [4] - In recent years, Revvity has significantly scaled its Life Sciences and Diagnostics businesses, expanding into large molecule capabilities and diversifying the Diagnostics portfolio beyond reproductive health [4]

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - Revvity has undergone significant transformation over the past decade, evolving from a company with equal focus on analytical, life sciences, and diagnostics to a balanced portfolio of approximately $3 billion, split evenly between life sciences and diagnostics [2][4] - The life sciences business has expanded into large molecule capabilities, while diagnostics has diversified beyond reproductive health into autoimmune, allergy, and emerging diseases [3] Financial Performance - Revvity's revenue is approximately $3 billion, with 85% of the portfolio being recurring revenue [4] - The life sciences segment generates about $1.5 billion, with 85% from innovative reagents and instrumentation, and 15% from software [5] - The diagnostics segment also contributes around $1.5 billion, with 60% from immunodiagnostics and 40% from reproductive health [6] Growth Drivers - Revvity identifies four key growth pillars: 1. **Software Business**: Launching new products like Xynthetica, BioDesign, and Signals LabGistics, which are expected to enhance drug discovery and lab management [8][9][10] 2. **Immunodiagnostics**: Targeting a market share increase from 20% to 40% in the U.S. [11] 3. **GMP Innovation**: Building capabilities in Good Manufacturing Practices, with expectations for significant growth in the coming years [11][41] 4. **Strategic Partnerships**: Collaborations with companies like Sanofi and Genomics England to enhance service offerings [10] Market Outlook - Revvity anticipates organic growth of 2%-3% for 2026, with expectations of low single-digit growth in life sciences solutions and mid-single-digit growth in reproductive health [30][35] - The company does not expect a market recovery in pharma and biotech for 2026, but sees potential for growth in other areas [33] Operational Excellence - Revvity has improved free cash flow conversion to approximately 90% from a historical 70% [12] - The company plans for a 100 basis point margin expansion in 2026, with further expansion expected in 2027 due to cost benefits [13][68] AI and Drug Development - Revvity views AI as a net tailwind for both its reagents and software businesses, facilitating drug discovery and creating a validation bottleneck that will increase demand for wet lab services [20][26] - The company is positioned to leverage AI through its software offerings, creating a marketplace for AI models that integrates with existing lab research [21][25] Competitive Landscape - Revvity maintains a competitive advantage through best-in-class customer service, rapid delivery of reagents, and a strong innovation pipeline [44][45] - The company is monitoring competitive disruptions from industry transactions, such as the Waters BD transaction, but believes its moat remains strong [44] Challenges and Risks - The company has adopted a more prudent approach to growth assumptions in the Chinese market due to regulatory changes [58] - Potential tariff impacts on diagnostics manufacturing in Europe are being monitored, with plans to mitigate exposure [63] Conclusion - Revvity is optimistic about its growth trajectory, driven by innovation, strategic partnerships, and operational improvements, while navigating challenges in the pharma and biotech markets [16][70]